tiprankstipranks

Mark Alan Goldberg Insider Profile

11 Followers
Mark Alan Goldberg, Director at ImmunoGen, holds 0.00 shares in ImmunoGen (Ticker: IMGN), holds 31.74K shares in GlycoMimetics (Ticker: GLYC), holds 16.01K shares in Blueprint Medicines (Ticker: BPMC).
tipranks
Mark Alan Goldberg

Mark Alan Goldberg
ImmunoGen (IMGN)
Director

Ranked #11,626 out of 97,825 Corporate Insiders

Profitable Transactions

40%
2 out of 5 Profitable Transactions

Average Return

+33.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$2M
93.76%
6.24%
A breakdown of Mark Alan Goldberg's holdings

Insider Roles

Blueprint Medicines
(BPMC)
Director
GlycoMimetics
(GLYC)
Director
Roles that Mark Alan Goldberg holds in companies

Most Profitable Insider Trade

Stock:
ImmunoGen
(IMGN)
Rating:Informative Buy
Date:Dec 15, 2016 - Dec 15, 2017
Return:+280.40%
The most profitable trade made by Mark Alan Goldberg

Mark Alan Goldberg's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
IMGN
ImmunoGen
Feb 12, 2024
Uninformative Sell
$0.00
BOLD
Audentes Therapeutics
Jan 15, 2020
Uninformative Sell
90.00K
$0.00
GlycoMimetics
Jan 02, 2024
Director
Uninformative Buy
13.75K
$100.94K
ACGN
Aceragen
Apr 05, 2021
Uninformative Buy
13.87K
$18.47K
Blueprint Medicines
Jun 23, 2023
Director
Uninformative Buy
$1.52M
GEVA
Synageva
Sep 19, 2014
Uninformative Sell
51.54K
List of latest transactions for each holding click on a transaction to see Mark Alan Goldberg's performance on stock

Mark Alan Goldberg insider profile FAQ

What is the percentage of profitable transactions made by Mark Alan Goldberg?
The percentage of profitable transactions made by Mark Alan Goldberg is 40%.
    What is the average return per transaction made by Mark Alan Goldberg?
    The average return per transaction made by Mark Alan Goldberg is 33.60%.
      What stocks does Mark Alan Goldberg hold?
      Mark Alan Goldberg holds: IMGN, BOLD, GLYC, ACGN, BPMC, GEVA stocks.
        What was Mark Alan Goldberg’s latest transaction?
        Mark Alan Goldberg latest transaction was an Uninformative Sell of ―.
          What was Mark Alan Goldberg's most profitable transaction?
          Mark Alan Goldberg’s most profitable transaction was an Informative Buy of IMGN stock on December 15, 2016. The return on the trade was 280.40%.
            What is Mark Alan Goldberg's role in ImmunoGen?
            Mark Alan Goldberg's role in ImmunoGen is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.